Prospective Cohort Study of Arthroscopic Treatment of Hip Dysplasia
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Jul 16, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a minimally invasive surgical treatment for patients with a condition called borderline developmental dysplasia of the hip, which can lead to joint problems. The goal is to improve how these surgeries are performed and to help patients recover more quickly and effectively. By collecting and analyzing data from previous patients, researchers hope to refine the process, making it easier for those affected by this condition to regain their mobility and strength.
If you or someone you know has been diagnosed with borderline hip dysplasia and has an injury to the area around the hip joint, you might be eligible to participate in this study. The trial is currently recruiting participants of all ages and genders. Those who join can expect to undergo a minimally invasive procedure and will be closely monitored throughout their recovery. This research aims to not only enhance treatment options but also contribute to better overall health and fitness for individuals with hip dysplasia.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Diagnosis of borderline hip dysplasia with glenolabial injury.
- Exclusion Criteria:
- • -
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Trial Officials
Jianquan J Wang, M.D.
Study Chair
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported